

8-K 1 d8k.htm FORM 8-K

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): April 4, 2008

Novacea, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction
of incorporation)

000-51967
(Commission
File Number)

**400 Oyster Point Boulevard, Suite 200
South San Francisco, California 94080**
(Address of Principal Executive Offices)

(650) 228-1800
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 1.02. Termination of a Material Definitive Agreement

On April 4, 2008, Schering Corporation (“Schering”), a wholly-owned subsidiary of Schering-Plough Corporation, delivered written notice of Schering’s termination of the exclusive License, Development and Commercialization Agreement between Novacea, Inc. (“Novacea” or the “Collaboration Agreement”) dated May 29, 2007, for the development and commercialization of Asentar™ (DN-101) for all diagnostic, therapeutic and prophylactic uses in humans (the “Collaboration Agreement”). Schering elected to terminate the Collaboration Agreement pursuant to Section 16.4(b) based on Schering’s determination, related to the ASCENT-2 Phase 3 clinical trial, that there had been a technical failure related to Asentar™. In November 2007, Novacea and Schering terminated the Collaboration Agreement and Asentar™ due to an unexplained imbalance of deaths between the treatment and control arms of the trial.

According to the Termination Letter, the termination was effective immediately upon Novacea’s receipt of the Termination Letter. Upon termination of the Collaboration Agreement, the licenses and other rights granted by Novacea to Schering pursuant to the Collaboration Agreement terminated and Schering began an orderly wind-down of all ongoing development activities with respect to Asentar™ and making all payments due to Novacea and any other third parties as per the terms of the Collaboration Agreement. Novacea anticipates that Schering will honor invoices for all costs incurred through the effective date of termination. Schering has indicated that they may dispute the costs associated with the currently ongoing wind-down activities with respect to Asentar™, which Novacea will pay to Novacea subsequent to the effective date of termination and subject to reimbursement by Schering. Any future development of Asentar™ would be the responsibility of Novacea. Novacea does not anticipate incurring any early termination penalties as a result of the termination of the Collaboration Agreement.

As a result of the termination of the Collaboration Agreement, Novacea anticipates that it will recognize as revenue in 2008 the entire amount of approximately \$60.0 million (as of December 31, 2007) related to the \$60.0 million in upfront payments, which were being amortized previously over an approximate period of 10 years.

Novacea disclosed the material terms of the Collaboration Agreement and filed a copy of the Collaboration Agreement in its current report on Form 8-K filed with the Securities and Exchange Commission on June 1, 2007.

The foregoing description is qualified in its entirety by reference to the Company’s press release dated April 9, 2008, a copy of which is incorporated herein by reference.

* * * * *

Forward-Looking Statements. This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934. These statements relate to future events or our future clinical or product development, financial performance, or product candidates, or commercialization efforts. In some cases, you can identify forward-looking statements by

terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “contingent” and other comparable terminology. These statements reflect only management’s current expectations. Important factors that could cause actual results to differ from the forward-looking statements we make or incorporate by reference in this report are set forth under the heading “Risk Factors” in our most recent Form 10-K, as may be updated from time to time by our future filings under the Securities Exchange Act. If one or more of these risks or uncertainties materialize, or our underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements contemplated in these forward-looking statements. We disclaim any intent or obligation to update these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release dated April 9, 2008

10/13/2016

Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by a duly authorized person.

Date: April 9, 2008

NOVACEA, INC.

By: /s/ Edward C. Albini

Name: Edward C. Albini

Title: Chief Financial Officer

10/13/2016

Form 8-K

EXHIBIT INDEX

Exhibit No.**Description**

99.1 Press Release dated April 9, 2008